Risperidone long-acting injectable (RLAI) administration in deltoid muscle…. really is an improvement?

2011 ◽  
Vol 26 (S2) ◽  
pp. 1223-1223
Author(s):  
S. Arques ◽  
F. Arnau ◽  
T. Rubio ◽  
A. Pino ◽  
C. Iranzo
Keyword(s):  
Patient Satisfaction ◽  
Adverse Events ◽  
Psychotic Disorders ◽  
Deltoid Muscle ◽  
List Type ◽  
Global Satisfaction ◽  
Clinical Patient ◽  
Therapeutic Decisions ◽  
Long Acting ◽  
The Impact

IntroductionIn the treatment of psychotic disorders, any such instrument or way that could help to improve their prognosis should be valued and taken into account.ObjectivesTo determine the impact of the administration of RLAI in the deltoid, assessing patient satisfaction and acceptance, as well as efficacy and tolerability.Material and methodsProspective, naturalistic and descriptive, 20 patients with chronic psychosis treated with RLAI, performing a change in administration (gluteal to deltoid muscle).We realize 2 valuations:1Basal: demographic, clinical (PANSS, CGI, UKU, dose and duration RLAI).2Final (6 months): clinical, patient satisfaction (Questionnaire Medication Treatment Satisfaction, Visual Analogue Scale VAS).Analysis SPSS v15.0.ResultsIn subscales TSQM, punctuations very raised for deltoid: Efficiency 75, 55 %; adverse events 94, 38 %; Administration 75, 27 %; Global satisfaction 74, 64%. The VAS of satisfaction with deltoid was of 7′ 4 ± 1′ 3 (0–10).Opinion patientsless pain, adverse events and more normal (100%), more capacity decision (80%), less stigmatizing (85%).No differences in efficacy, but better tolerated.ConclusionsThe administration of the deltoid RLAI in can be a useful tool for the treatment of psychotic disorders because it can allow the patient to engage in certain therapeutic decisions (to be able to choose the way), promote adherence, may improve the perception of treatment to be associated deltoid administration to something less traumatic and stigmatizing, that is “more normal.”

P.464 The impact of long-acting injectable aripiprazole in the management of psychotic disorders

2020 ◽  
Vol 40 ◽  
pp. S262-S263
Author(s):  
Á.D.L. Martín Pérez ◽  
M.I. Ibernón Caballero ◽  
M.Á. Bernal López ◽  
K.A. Rozmus X ◽  
F. Valdivia Muñoz ◽  
...  
Keyword(s):  
Psychotic Disorders ◽  
Long Acting ◽  
The Impact

scholarly journals 008 Associations between comorbidities and adverse events of antiepileptic drugs and quality of life: a survey of epilepsy patients in australia

2019 ◽  
Vol 90 (e7) ◽  
pp. A3.2-A3
Author(s):  
Jeremy M Welton ◽  
Christine Walker ◽  
Kate Riney ◽  
Alvin Ng ◽  
Lisa M Todd ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Adverse Events ◽  
Antiepileptic Drugs ◽  
List Type ◽  
Linear Regression Models ◽  
Cross Sectional ◽  
Stepwise Selection ◽  
Memory Problems ◽  
The Impact

IntroductionThis study explored the impact of specific types of comorbidities and adverse events (AEs) from antiepileptic drugs (AEDs) on quality of life (QoL) among adult patients with epilepsy (PwE) in Australia.MethodsCross-sectional surveys were completed by PwE, or caregiver proxies, recruited via the online pharmacy application MedAdvisor and Australian PwE Facebook groups from May–August 2018 Data were collected on demographics, epilepsy severity and management, AEs, comorbidities, and QoL (using QOLIE-10-P total score).1 Multiple linear regression models were constructed to explore associations between AEs or comorbidities and QOLIE-10-P, with possible confounders determined using stepwise selection.Results978 responses were included (mean age 44.5 years, 64% female, 52% employed). 97% reported recent AED use, 47% on AED monotherapy, 35% exposed to ≤2 lifetime AEDs, and 55% seizure-free for >1 year. After stepwise selection, control variables included in both models were: time since diagnosis, employment status, seizure frequency, number of currently prescribed AEDs, and number of general practitioner visits per year. In the model for comorbidities, ‘psychiatric disorders’ was associated with the largest QOLIE-10-P decrease (-23.30, p<0.001). In the model for AEs, which additionally controlled for depression and anxiety disorder, ‘memory problems’ was associated with the largest decrease in QOLIE-10-P (-14.27, p<0.001).ConclusionsIn this survey of Australian PwE, of which many had relatively well-controlled epilepsy, psychiatric and memory problems were common and associated with the greatest detrimental impact on QoL. Further research is needed to understand causality, relationships between possibly interrelated or overlapping symptoms, and management strategies. UCB Pharma-sponsored.ReferenceCramer JA, Perrine K, Devinsky O, Meador K. A brief questionnaire to screen for quality of life in epilepsy: The QOLIE-10. Epilepsia 1996;37:577–582.

From Fable to Reality at Parkland Hospital: The Impact of Evidence-Based Design Strategies on Patient Safety, Healing, and Satisfaction in an Adult Inpatient Environment

2020 ◽  
pp. 193758672097019
Author(s):  
Renae K. Rich ◽  
Francesqca E. Jimenez ◽  
Susan E. Puumala ◽  
Sheila DePaola ◽  
Kathy Harper ◽  
...  
Keyword(s):  
Patient Safety ◽  
Patient Satisfaction ◽  
Adverse Events ◽  
Noise Temperature ◽  
Evidence Based ◽  
Patient Acuity ◽  
Hospital Design ◽  
Inpatient Outcomes ◽  
Adult Inpatient ◽  
The Impact

Objective: This research aimed to evaluate the quantitative effects of new hospital design on adult inpatient outcomes. Background: Tenets of evidence-based healthcare design, notably single-patient acuity-adaptable and same-handed rooms, decentralized nursing stations, onstage offstage layout, and access to nature were expected to promote patient healing and increase patient satisfaction, while decreasing adverse events. Methods: Patient healing was operationalized through length of stay (LOS) and patient safety through three adverse events: falls, hospital-acquired infections (HAI), and medication-related events. Standard patient surveys captured patient satisfaction. Patient records from 2013 through 2017 allowed for equivalent time periods surrounding the move to the new hospital in August 2015. Stratified by hospital division where significant, pre/post comparisons utilized proportional hazards or logistic regression models as appropriate; interrupted time series analyses afforded longitudinal interpretations. Results: Observed higher postmove LOS was due to previously increasing trends, not increases after the move. In surgical and trauma units, a constant increase in falls was unaffected by the move. Medication events decreased consistently over time; medication events with harm dropped significantly after the move. No change in HAI was found. Significant improvement on most relevant patient satisfaction items occurred after the move. Call button response decreased immediately after the move but subsequently improved. Conclusion: Results did not clearly indicate a net change in adult inpatient outcomes of healing and safety due to the hospital design. There was evidence that the new hospital improved patient satisfaction outcomes related to the environment, including comfort, noise, temperature, and aesthetics.

The side effects of risperidone depot in patients with psychotic disorders

2017 ◽  
Vol 41 (S1) ◽  
pp. s816-s816
Author(s):  
T. Jupe ◽  
F. Elezi ◽  
B. Zenelaj ◽  
E. Myslimi
Keyword(s):  
Side Effects ◽  
Negative Symptoms ◽  
Psychotic Disorders ◽  
Statistical Processing ◽  
Drug Dose ◽  
Strong Positive Correlation ◽  
Duration Of Treatment ◽  
Positive Correlation ◽  
Long Acting ◽  
The Impact

Background and aimA long-acting form of risperidone is now broadly available for the treatment of schizophrenia and closely related psychiatric conditions. It combines the advantage of previously available depot formulations for first-generation drugs with the favorable characteristics of the modern “atypical” antipsychotics, namely higher efficacy in the treatment of the negative symptoms of schizophrenia and reduced motor disturbances [1].MethodsDuring this study, we observed side effects that appear in patients that are treated with risperidone depot. Patients were observed for a period of 3 months (October–December 2015) and the side effects were evaluated with Glasgow Antipsychotic Side-effect Scale (GASS). The data obtained were analyzed with SPSS, trying to prove the impact of variables such as: gender, age, diagnosis, dose and duration of treatment on the occurrence of side effects.ResultsThrough statistical processing, we reached the conclusion that there is a statistically significant correlation between duration of treatment and side effects (P value was 0.0001). Between two variables has a strong positive correlation (Kendall value was 0.766). Has a statistically significant correlation between the drug dose and side effects (P value was 0.026). Between two variables has a moderate positive correlation (Kendall value was 0.504). No statistically significant correlation between these variables: gender-side effects, diagnose-side effects and age-side effects.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Implementation and Evaluation of Virtual Anticoagulation Clinic Care to Provide Incessant Care During COVID-19 Times in an Indian Tertiary Care Teaching Hospital

2021 ◽  
Vol 8 ◽  
Author(s):  
Sunil Kumar Shambu ◽  
Shyam Prasad Shetty B ◽  
Oliver Joel Gona ◽  
Nagaraj Desai ◽  
Madhu B ◽  
...  
Keyword(s):  
Patient Satisfaction ◽  
Adverse Events ◽  
Data Exchange ◽  
Vitamin K Antagonists ◽  
Tertiary Care ◽  
Anticoagulation Clinic ◽  
Public Health Services ◽  
Significant Difference ◽  
The Mean ◽  
The Impact

Background: COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-II) has become a global pandemic disrupting public health services. Telemedicine has emerged as an important tool to deliver care during these situations. Patients receiving Vitamin K antagonists (VKA) require structured monitoring which has posed a challenge during this pandemic. We aimed to evaluate the impact of Virtual anticoagulation clinic (VAC), a Telehealth model on the quality of anticoagulation, adverse events, and patient satisfaction vis-a-vis standard Anticoagulation clinic (ACC) care.Materials and methods: A bidirectional cohort study was conducted in the Department of Cardiology, JSS Hospital, Mysore. Two hundred and twenty-eight patients in the VAC and 274 patients in the ACC fulfilling inclusion criteria were the subjects of the study. Telehealth tools like WhatsApp and telephone were used. Time in therapeutic range (TTR), Percentage of International normalized ratio in range (PINRR), and adverse events were analyzed and compared between the VAC group and the ACC group, between pre-COVID and COVID ACC groups, and between the VAC group and the same pre-COVID cohort. Patient satisfaction was assessed by a questionnaire at the end of 8 months. Descriptive statistics were used for the patient characteristics and inferential statistics for the comparisons between pre-VAC and VAC care.Results: The mean TTR was 75.4 ± 8.9% and 71.2 ± 13.4% in the VAC group and ACC group, respectively (p &lt; 0.001). The mean PINRR was 66.7 ± 9.4% and 62.4 ± 10.9% in the VAC group and ACC group respectively, (p &lt; 0.001). There was no significant difference in TTR between the VAC group and the same pre-COVID cohort. The TTR differential between the pre-COVID and COVID ACC groups was significant. In either group, no major adverse events were seen. The most common tools used for data exchange were WhatsApp (83%) and SMS (17%). Seventy-four percent of patients were extremely satisfied with the overall VAC care.Conclusions: Virtual anticoagulation clinic, a telehealth model can be used as an alternative option to deliver uninterrupted anticoagulation care during pandemic times.

scholarly journals A description of the use of zuclopenthixol decanoate long-acting injection in a large mental health trust

BJPsych Open ◽  
2021 ◽  
Vol 7 (S1) ◽  
pp. S340-S340
Author(s):  
Shay-Anne Pantall ◽  
Emily Whitehouse ◽  
Lisa Brownell
Keyword(s):  
Mental Health ◽  
Adverse Effects ◽  
Psychotic Disorders ◽  
Bipolar Affective Disorder ◽  
Primary Diagnosis ◽  
Patient Choice ◽  
List Type ◽  
Retrospective Case ◽  
Long Acting ◽  
Zuclopenthixol Decanoate

AimsAdherence with antipsychotic medication is an important factor in the prevention of relapse in psychotic disorders such as schizophrenia. Long acting antipsychotic injections promote improved adherence. In recent years, second generation antipsychotic long-acting injections have become increasingly popular, and little has been written about the use of the older depot medications. Here, we explore the current use of one of the first-generation antipsychotic long acting injections in Birmingham and Solihull Mental Health NHS Foundation Trust.MethodAn 18-month retrospective case-note review of all patients who started zuclopenthixol decanoate during the first 6 months of 2018 (n = 45)ResultKey findings included: - ⋅71% were male⋅The mean age was 37 (range 19-65)⋅The most common diagnoses were: schizophrenia (51%), bipolar affective disorder (18%) and schizoaffective disorder (13%). We noted that 2 individuals (4%) had a primary diagnosis of recurrent depressive disorder, 2 (4%) had a primary diagnosis of emotionally unstable personality disorder.⋅60% of those who were prescribed zuclopenthixol decanoate discontinued it within the 18-month follow-up period.⋅The vast majority of discontinuation occurred within the first 6 months, and after this, few individuals stopped treatment.⋅The most common reason for discontinuation was side effects (57%), with other reasons including patient choice (7%), non-compliance (7%), pregnancy (4%), or needle phobia (4%).ConclusionZuclopenthixol decanoate has been used for individuals with both schizophrenia and paranoid psychosis (where it is licenced) and also occasionally for other indications. A high proportion discontinued the zuclopenthixol within 6 months, this generally being attributed to adverse effects. Those who were still receiving this medication at 6 months were very likely to continue to take it throughout the 18 months. We would therefore recommend robust monitoring for and management of adverse effects in the early phases of treatment.

52 Drug therapy for delirium in terminally ill adults: a cochrane systematic review

2018 ◽  
Vol 8 (3) ◽  
pp. 379.2-380
Author(s):  
A Finucane ◽  
L Jones ◽  
B Leurent ◽  
E Sampson ◽  
P Stone ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Adverse Events ◽  
Small Sample Size ◽  
Cochrane Review ◽  
Terminally Ill ◽  
Outcome Data ◽  
Small Sample ◽  
List Type ◽  
The Impact ◽  
Ill Adults

IntroductionDelirium is a complex neuropsychiatric syndrome common in palliative care occurring in up to 88% of patients in the weeks or hours preceding death. Our Cochrane review on drug therapy for delirium in 2012 identified one trial (Candy et al. 2012). New trials have been conducted and an updated review is now recognised as a Cochrane priority.AimTo evaluate the evidence from randomised controlled trials (RCTs) examining the effectiveness and safety of drug therapies to treat delirium in adults with a terminal illness.MethodsWe searched for RCTs comparing any drug treatment with any other treatment for delirium in terminally ill adults. Primary outcomes included delirium symptoms at 24 hours and between 24–48 hours; and adverse events. Risk of bias assessment was conducted; we assessed overall quality of evidence using GRADE.ResultsWe retrieved 9431 citations. Four studies were included in the final review. All trials were vulnerable to bias most commonly due to small sample size or incomplete outcome data. Figures 1 and 2 illustrate the mean difference between trial arms at 24 hours and between 24–48 hours respectively. Three studies reported adverse events revealing mixed results.Abstract 52 Figure 1Abstract 52 Figure 2ConclusionThis review identified four trials. It found low quality evidence examining the impact of drug therapy on delirium symptoms and adverse events in terminally ill adults. Results for each comparison were based on single studies. Undertaking trials on delirium in this patient group is methodologically complex. Only one study compared drug therapy with placebo. This limited our ability to answer our review questions.Reference. Candy B, Jackson KC, Jones L, Leurent B, Tookman A, King M. Drug therapy for delirium in terminally ill adult patients. Cochrane Database of Systematic Reviews2012;(11). Art. No. CD004770. doi:10.1002/14651858.CD004770.pub2

SPECIAL PROBLEMS IN TOXICITY TESTING OF LONG ACTING DEPOT CONTRACEPTIVES

1974 ◽  
Vol 77 (1_Suppla) ◽  
pp. S315-S354 ◽  
Author(s):  
F. Neumann ◽  
R. von Berswordt-Wallrabe ◽  
W. Elger ◽  
K.-J. Gräf ◽  
S. H. Hasan ◽  
...  
Keyword(s):  
Biological Effects ◽  
Histological Finding ◽  
Toxicity Testing ◽  
Prolactin Secretion ◽  
List Type ◽  
Human Species ◽  
Prolactin Plasma Level ◽  
Human Use ◽  
Long Acting ◽  
Reproductive Processes

ABSTRACT Two types of so-called "depot contraceptives", long-acting steroids which are of interest for human use, were studied in animals. Norethisterone oenanthate, mainly gestagenic in the human and other species, turned out to be predominantly oestrogenic in rats. This oestrogenicity caused indirectly, via an enhanced hypophysial prolactin secretion, the well-known hypophysial and mammary tumours in rats. Another synthetic gestagen, 4,6-dichloro- 17- acetoxy- 16α-methyl-4,6-pregnadiene-3,20-dione, which might be considered in its biological actions similar to preparations containing chlormadinone acetate or medroxy-progesterone acetate, induced no signs of oestrogenicity in dogs. It is surmised that its gestagenic influence indirectly, and probaby, via an enhanced hypophysial prolactin secretion caused "mammary nodules" in this "non-rodent" species. These studies have born out mainly two facts: A synthetic steroid, norethisterone oenanthate, exerted different biological effects in different species: it was a gestagen in the rabbit, whereas in rats, its predominant influence was oestrogenic. The hypophysial prolactin secretion was enhanced in various species by different mechanisms: in rats, the oestrogenicity caused an increased prolactin plasma level, whereas in dogs, a gestagen with obviously no inherent oestrogenicity, 4,6-dichloro-17-acetoxy-16α-methyl-4,6-pregnadiene-3,20-dione, converted the histological appearance of the anterior pituitary into a condition with a greatly increased number of eosinophils. This histological finding was interpreted as an indicator for a hypersecretion of prolactin. Hence, animal work with "gestagens" has only limited predictive value with respect to their possible effects in the human species. Therefore, inflexible recommendations are not helpful in solving the safety problem of long-acting steroids which affect primarily reproductive processes.

Sign in / Sign up

Export Citation Format

Share Document